- Home
- FTV vs WAT Comparison
FTV vs WAT Comparison
Compare FTV & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTV
- WAT
- Stock Information
- Founded
- FTV 2015
- WAT 1958
- Country
- FTV United States
- WAT United States
- Employees
- FTV N/A
- WAT N/A
- Industry
- FTV Industrial Machinery/Components
- WAT Biotechnology: Laboratory Analytical Instruments
- Sector
- FTV Industrials
- WAT Industrials
- Exchange
- FTV Nasdaq
- WAT Nasdaq
- Market Cap
- FTV 23.9B
- WAT 17.8B
- IPO Year
- FTV N/A
- WAT 1995
- Fundamental
- Price
- FTV $48.79
- WAT $303.13
- Analyst Decision
- FTV Hold
- WAT Hold
- Analyst Count
- FTV 13
- WAT 14
- Target Price
- FTV $62.50
- WAT $374.07
- AVG Volume (30 Days)
- FTV 3.8M
- WAT 582.9K
- Earning Date
- FTV 10-29-2025
- WAT 10-31-2025
- Dividend Yield
- FTV 0.66%
- WAT N/A
- EPS Growth
- FTV N/A
- WAT 10.77
- EPS
- FTV 2.22
- WAT 11.09
- Revenue
- FTV $6,147,900,000.00
- WAT $3,046,056,000.00
- Revenue This Year
- FTV N/A
- WAT $7.19
- Revenue Next Year
- FTV $3.51
- WAT $6.40
- P/E Ratio
- FTV $21.90
- WAT $26.89
- Revenue Growth
- FTV N/A
- WAT 5.89
- 52 Week Low
- FTV $45.51
- WAT $275.05
- 52 Week High
- FTV $62.79
- WAT $423.56
- Technical
- Relative Strength Index (RSI)
- FTV 52.43
- WAT 52.90
- Support Level
- FTV $47.01
- WAT $294.96
- Resistance Level
- FTV $49.75
- WAT $303.24
- Average True Range (ATR)
- FTV 0.91
- WAT 8.97
- MACD
- FTV 0.21
- WAT 0.70
- Stochastic Oscillator
- FTV 70.20
- WAT 68.90
About FTV Fortive Corporation
Fortive is a diversified industrial technology firm with a broad portfolio of mission-critical products and services that include field solutions, product realization, health, and sensing technologies. The company serves a wide range of end markets, including manufacturing, utilities, medical, and electronics. Fortive generated roughly $6.2 billion in revenue in 2024.
About WAT Waters Corporation
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2024, Waters generated 58% from biopharmaceutical customers, 31% from industrial clients, and 11% from academic/government institutions. In early 2026, Waters plans to merge with BD's life science and diagnostics business, which will substantially change those concentrations. Waters will wind up with more concentration in diagnostics (versus none now) and discovery-related life science tools.